Raymond James & Associates’s CureVac CVAC Stock Holding History

Raymond James & Associates’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,183	Closed	-$234K	–	4149
2021 Q2	$234K	Buy	+3,183	New	+$318K	﹤0.01%	3591

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Raymond James & Associates's CVAC Position: Q3 2021 in Review

Raymond James & Associates sold out of CureVac (CVAC) in Q3 2021, closing a stake of 3,183 shares — an estimated $234K sold.

Raymond James & Associates first reported a position in CVAC in Q2 2021 and held it in 1 quarter. The position peaked at $234K in Q2 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q3 2021.

Raymond James & Associates reported no remaining CureVac position as of Q3 2021 after selling out during the quarter.
Raymond James & Associates sold 3,183 CureVac shares in Q3 2021, an estimated $234K.
Raymond James & Associates first reported a position in CureVac in Q2 2021 and held it in 1 quarter.
Raymond James & Associates's CureVac position peaked at $234K in Q2 2021.
111 funds tracked by Wall St. Rank held CureVac as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.